Company Reports Q1 Revenue of Only $15K
Reports Q1 revenue $15K, consensus $861K. Cash, cash equivalents and marketable securities as of March 31, were $451.5M compared to $518.6M as of December 31, 2025. "We began the year with a significant milestone - the early completion of enrollment in our Phase 3 CSU studies - and we have continued to build on that momentum over the quarter," said Anthony Marucci, CEO. "This spring, barzolvolimab was featured in five presentations at leading medical meetings, further reinforcing its potential as a first-in-class, best-in-disease therapy with the ability to transform the treatment landscape for patients in need of better options. This progress enabled the successful completion of a $345M financing in early April, strengthening our balance sheet and supporting continued investments in our commercialization preparations and growing pipeline."
